Investigational MS medicines: Biogen has several candidates in Phase 1 and 2 clinical trials in neurodegenerative and immunological diseases including MS
A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS). Biogen logo. Biogen. Status. Begins
dramatically increasing their prices for drugs used to treat Multiple Sclerosis (MS), which is a Biogen's newest drug. Zinbryta, was
Biogen will take over development of an Alkermes small-molecule drug for multiple sclerosis (MS). The compound, ALKS 8700, is in Phase III
The launch of Ocrevus, a new MS drug by Roche RHHBY, is adversely impacting sales of Biogen s MS franchise. The MS drug from Roche was approved by the FDA in 2024 and generated CHF 3.7 billion
The deal raises Biogen Idec's presence in MS drugs at a time when it is also seeking FDA approval for another drug against MS, Tecfidera
The FDA has approved an intramuscular formulation of Biogen s multiple sclerosis drug Plegridy. Biogen is framing the formulation as a way for relapsing MS patients to treat their conditions
As for Biogen's other MS drugs, Avonex (interferon beta-1a) slipped 2% at $736.0 million, while Tysabri (natalizumab) contributed $483.9
A former Biogen employee claimed the company rewarded doctors with kickbacks for prescribing Biogen's MS drugs.
Comments
Always a living fan,
Santacruzman